FDA Approves First Plasmid DNA Immunotherapy for Recurrent Respiratory Papillomatosis
The FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.
The FDA approved the first plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis.